West Pharmaceutical (WST) CEO logs stock grants, RSU conversions and tax share disposals

Rhea-AI Filing Summary

West Pharmaceutical Services President and CEO Eric Mark Green reported several equity-related transactions. On February 17, 2026, he acquired 4,418.771 shares of common stock as a grant. On February 18, 2026, 1,318.810 restricted stock units, stemming from 2023–2025 performance stock units, converted into common stock on a one-for-one basis. To cover tax obligations, he disposed of 1,305.382 shares at $243.19 and 573.551 shares at $248.26. Following these transactions, he directly owned 175,160.6588 common shares and indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan.

Insider Trade Summary

1,318.81 shares exercised/converted

Mixed 6 txns

Insider Green Eric Mark

Role President, CEO and Board Chair

Type	Security	Shares	Price	Value
Exercise	Rst. Stock Unit	1,318.81	$0.00	--
Exercise	Common Stock	1,318.81	$0.00	--
Tax Withholding	Common Stock	573.551	$248.26	$142K
Grant/Award	Common Stock	4,418.771	$0.00	--
Tax Withholding	Common Stock	1,305.382	$243.19	$317K
holding	Common Stock	--	--	--

Holdings After Transaction: Rst. Stock Unit — 3,956.409 shares (Direct); Common Stock — 175,734.21 shares (Direct); Common Stock — 257.375 shares (Indirect, Non-Qualified Deferred Compensation Plan)

Footnotes (1)

1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown. Restricted stock units convert into common stock on a one-for-one basis. On February 18, 2025, the reporting person was granted 5,256 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Eric Mark

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Board Chair

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		4,418.771(1)	A	$0	174,199.9905	D
Common Stock	02/17/2026		F		1,305.382	D	$243.19	172,894.6085	D
Common Stock	02/18/2026		M		1,318.81	A	(2)	175,734.2098	D
Common Stock	02/18/2026		F		573.551	D	$248.26	175,160.6588	D
Common Stock								257.375	I	Non-Qualified Deferred Compensation Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(2)	02/18/2026		M			1,318.81	(3)	(3)	Common Stock	1,318.81	$0	3,956.409	D

Explanation of Responses:

1. These shares result from performance stock units (PSUs) which vested at the end of the respective 2023-2025 PSU performance period and were payable on the transaction date shown.

2. Restricted stock units convert into common stock on a one-for-one basis.

3. On February 18, 2025, the reporting person was granted 5,256 restricted stock units, vesting in four equal annual installments (plus dividend equivalents).

	/s/ Louis Lalli, as an agent for Eric Green	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Eric Mark Green report for WST?

Eric Mark Green reported equity grants, RSU conversions, and tax-related share dispositions. He received 4,418.771 common shares as a grant and 1,318.810 shares from vested performance stock units, while shares were withheld to satisfy tax obligations on these awards.

How many West Pharmaceutical (WST) shares did the CEO acquire?

Eric Mark Green acquired 4,418.771 shares of West Pharmaceutical common stock as a grant and 1,318.810 shares via conversion of restricted stock units. These awards reflect compensation rather than open-market purchases, increasing his reported equity stake in the company.

Were any West Pharmaceutical (WST) shares sold in the Form 4 filing?

The filing shows share dispositions coded as tax-withholding, not open-market sales. Specifically, 1,305.382 shares at $243.19 and 573.551 shares at $248.26 were delivered to cover tax liabilities arising from the reported stock grants and unit conversions.

What is Eric Mark Green’s reported WST share ownership after these transactions?

After the transactions, Eric Mark Green directly held 175,160.6588 shares of West Pharmaceutical common stock. He also indirectly held 257.375 shares through a Non-Qualified Deferred Compensation Plan, according to the ownership figures disclosed in the Form 4 filing.

What do the vested performance stock units mean for WST’s CEO?

The vested performance stock units represent compensation tied to a 2023–2025 performance period. Upon vesting, they produced 1,318.810 restricted stock units that converted into common stock on a one-for-one basis, increasing Eric Mark Green’s direct share ownership in West Pharmaceutical.

How were restricted stock units treated in the WST Form 4?

Restricted stock units converted into West Pharmaceutical common stock on a one-for-one basis. One transaction shows 1,318.810 units converting at no cash price, consistent with equity compensation awards that settle in shares rather than cash payments to the reporting executive.